Adma Biologics (ADMA) FY2016 results: revenue $11 million, up 48.5% on the year
Adma Biologics, Inc. (ADMA) reported revenue of $11 million for fiscal 2016, the year ended 31 December 2016, up 48.5% on the year before. Net income was -$20 million, and diluted earnings per share $-1.61. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2017.
Revenue
$11 million
+48.5% on the year
FY2011FY2016
Operating margin
-162.6%
-216.1% a year earlier
FY2011FY2016
Net income
-$20 million
FY2011FY2016
Diluted EPS
-$1.61
FY2011FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
10.7
7.2
5.9
+48.5%
Cost of revenue
1.6
4.3
3.7
-62.7%
Gross profit
4.3
2.9
2.2
+50.0%
Gross margin
40.3%
39.9%
36.7%
Research and development
7.7
7.0
9.5
+9.6%
Operating income
-17.3
-15.5
-16.0
Operating margin
-162.6%
-216.1%
-270.8%
Interest expense
2.2
1.8
1.3
+21.5%
Pre-tax income
-19.5
-18.0
-17.4
Income tax
0.0
0.0
-0.6
Net income
-19.5
-18.0
-16.8
Net margin
-183.1%
-250.4%
-284.2%
Diluted EPS
-$1.61
-$1.73
-$1.81
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-18.3
-15.4
-14.7
Capital expenditure
0.1
0.0
2.3
+181.6%
Free cash flow
-18.3
-15.4
-17.0
Free cash flow margin
-172.1%
-215.2%
-287.9%
Cash from investing
0.9
-1.7
-4.0
Cash from financing
16.8
10.4
9.8
+61.9%
Depreciation and amortisation
0.4
0.5
0.2
-14.9%
Share-based compensation
1.3
1.7
1.2
-26.9%
Shares outstanding at period end
13m
11m
9m
+20.3%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
-4.5
0.8
6.0
Debt
20.2
14.2
14.6
+41.9%
Other liabilities
7.9
8.6
6.4
-8.4%
Total liabilities and equity
23.7
23.7
27.0
-0.1%
Fixed assets
2.0
2.4
2.8
-16.5%
Goodwill
0.0
n/a
n/a
Intangible assets
0.0
n/a
n/a
Investments
5.4
6.4
4.7
-15.4%
Cash and equivalents
9.9
10.4
17.2
-5.0%
Receivables
1.0
0.9
0.4
+10.1%
Inventory
5.0
3.4
1.7
+45.7%
Other assets
0.3
0.1
0.2
+146.8%
Total assets
23.7
23.7
27.0
-0.1%
10-K for the year ended 31 December 2016, filed 24 February 2017: the filing.